サンプル依頼リスト カート
  • English
デフォルト表紙
市場調査レポート
商品コード
1727075

診断用AI：市場考察・競合情勢・市場予測 (2032年)

Artificial Intelligence (AI) in Diagnostics - Market Insights, Competitive Landscape, and Market Forecast - 2032

出版日
発行
DelveInsight
ページ情報
英文 150 Pages
納期
2～10営業日
カスタマイズ可能
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=144.87円
診断用AI：市場考察・競合情勢・市場予測 (2032年)
出版日: 2025年04月01日
発行: DelveInsight
ページ情報: 英文 150 Pages
納期: 2～10営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

診断用AI市場は、は、コンポーネント (ハードウェア/ソフトウェア、サービス)、用途 (感染症診断、放射線診断、腫瘍学、心臓病学、その他)、技術 (機械学習、自然言語処理、その他)、地域 (北米、欧州、アジア太平洋、その他の地域) に分類され、2032年まで堅調なCAGRで成長すると予測されています。これは、感染症および慢性疾患の増加、デジタルヘルスや画像診断技術の採用拡大、世界中の主要企業による製品開発活動の活発化が背景にあります。

診断用AIの市場規模は、2024年に16億2,320万米ドルと評価されており、2025年から2032年の予測期間においてCAGR 22.31%で成長し、2032年には80億8,197万米ドルに達すると見込まれています。

感染症および慢性疾患の有病率が上昇していることにより、早期かつ正確な診断への需要が高まっており、AIはその中で、検出の精度を高め、より迅速な臨床判断を支援する重要な役割を果たしています。同時に、デジタルヘルスおよび画像診断技術の普及が進んでいることが、既存の医療ワークフローにAIツールを統合するための強固な基盤となっており、業務効率と診断精度の向上につながっています。さらに、機械学習の進歩や規制当局による支援の拡大を背景に、世界中の主要企業による製品開発活動も活発化しており、AIを活用した診断ソリューションの提供が広がりつつあります。これらの要因が相まって、より正確でタイムリー、かつスケーラブルな医療提供を実現することで、2025年から2032年の予測期間中におけるAI診断市場の大幅な成長が期待されています。

診断用AI：市場力学

WHOの提供するデータによると、2023年時点で、世界では推定3,990万人がHIVに感染しており、約130万人が新たにHIVを獲得しました。また、同じく2023年において、約1,080万人が結核 (TB) を発症したと報告されています。診断用AIは、TBおよびHIVのマネジメントを支援する上で、早期検出および効率的なモニタリングを可能にすることで重要な役割を果たしています。TBにおいては、AIが胸部X線画像やCTスキャンを解析し、感染パターンを特定することで、特に医療資源の限られた地域において放射線科医への依存を軽減します。HIVに関しては、AIが疾患の進行状況の追跡、治療反応の予測、共感染の検出を支援します。これにより、ワークフローが効率化され、診断の遅れが減少し、大規模なスクリーニングの実施も容易になります。

加えて、癌の世界的な発生率の上昇も、診断用AI市場の成長を促進する大きな要因となっています。癌診断は複雑な画像解析、病理情報、ゲノムデータを伴うため、AIの活用に最適な分野です。WHOの2024年のデータによると、2022年には世界で新たに2,000万件の癌症例が報告され、その中でも肺癌は最も多く、250万件で全体の12.4%を占めました。AI搭載の診断ツールは、CTスキャンやX線を用いて人間の目では見落とされる可能性のある微細な異常を検出する能力を持っています。AIアルゴリズムは、肺組織における結節、腫瘤、不規則なパターンを解析し、迅速かつ高精度な診断を実現します。

さらに、British Heart Foundation（2025年）のデータによると、世界では約6億4,000万人が心臓および循環器疾患を抱えているとされています。これらの疾患は、早期診断によって予後の改善や死亡率の低下が期待できるため、正確かつタイムリーな検出が求められます。AIツールは、CT、MRI、心エコーなどの医療画像を解析し、従来の手法よりも高い精度と効率で複雑なデータを解釈することで、診断プロセスへの統合が進んでいます。

また、デジタルヘルスおよび画像診断技術の普及は、医療診断の速度・精度・アクセス性を高めることで、診断用AI市場を後押ししています。AIアルゴリズムは、CT、MRI、X線などから得られる複雑な画像データを効率的に解析し、腫瘍、循環器、呼吸器といった分野における早期検出に貢献しています。たとえば、2024年12月には、GE HealthCareがRSNA 2024カンファレンスで発表したSonic DL AI MRIアルゴリズムが、脳、脊椎、整形外科、体幹部の画像診断において最大86%の高速化と画質向上を実現しました。

当レポートでは、世界の診断用AIの市場を調査し、市場概要、法規制環境、市場影響因子の分析、市場規模の推移・予測、各種区分・地域別の詳細分析、競合情勢、主要企業のプロファイルなどをまとめています。

目次

第1章 診断用AI：レポートイントロダクション

  • 調査範囲
  • 市場セグメンテーション
  • 市場の想定

第2章 診断用AI：エグゼクティブサマリー

  • 市場概要

第3章 競合情勢

第4章 規制分析

第5章 診断用AI：主要要因分析

  • 市場促進要因
    • 感染症および慢性疾患の増加
    • デジタルヘルスおよび画像技術の採用拡大
    • 世界の主要企業による製品開発活動の増加
  • 市場抑制要因と課題
    • データのプライバシーとセキュリティ
    • データの質と量の低さ
  • 診断用AI：の機会
    • 希少疾患や未診断疾患へのAI統合に関する継続的な研究開発

第6章 診断用AI：ポーターのファイブフォース分析

第7章 診断用AIの評価

  • コンポーネント別
    • ハードウェア/ソフトウェア
    • サービス
  • 用途別
    • 感染症診断
    • 放射線
    • 腫瘍
    • 心臓病
    • その他
  • 技術別
    • 機械学習
    • 自然言語処理
  • 地域別
    • 北米
    • 欧州
    • アジア太平洋
    • 世界のその他の地域

第8章 診断用AI：企業および製品プロファイル

  • Aidoc
  • Qure.ai
  • GE HealthCare
  • Siemens Healthineers
  • PathAI
  • Ibex
  • Owkin, Inc
  • Imagen Technologies
  • Aiforia
  • RADLogics
  • Terarecon, Inc.
  • Prenosis, Inc.
  • Ibex
  • Google LLC
  • GE HealthCare
  • DreaMed
  • Riverain Technologies
  • Terarecon, Inc.
  • Aiforia
  • RADLogics

第9章 KOLの見解

第10章 プロジェクトアプローチ

第11章 DelveInsightについて

第12章 免責事項・問い合わせ

図表

List of Tables

  • Table 1: Competitive Analysis
  • Table 2: Artificial Intelligence (AI) in Diagnostics Market in Global (2022-2032)
  • Table 3: Artificial Intelligence (AI) in Diagnostics Market in Global by Component (2022-2032)
  • Table 4: Artificial Intelligence (AI) in Diagnostics Market in Global by Application (2022-2032)
  • Table 5: Artificial Intelligence (AI) in Diagnostics Market in Global by Technology (2022-2032)
  • Table 6: Artificial Intelligence (AI) in Diagnostics Market in Global by Geography (2022-2032)
  • Table 7: Artificial Intelligence (AI) in Diagnostics Market in North America (2022-2032)
  • Table 8: Artificial Intelligence (AI) in Diagnostics Market in the United States (2022-2032)
  • Table 9: Artificial Intelligence (AI) in Diagnostics Market in Canada (2022-2032)
  • Table 10: Artificial Intelligence (AI) in Diagnostics Market in Mexico (2022-2032)
  • Table 11: Artificial Intelligence (AI) in Diagnostics Market in Europe (2022-2032)
  • Table 12: Artificial Intelligence (AI) in Diagnostics Market in France (2022-2032)
  • Table 13: Artificial Intelligence (AI) in Diagnostics Market in Germany (2022-2032)
  • Table 14: Artificial Intelligence (AI) in Diagnostics Market in United Kingdom (2022-2032)
  • Table 15: Artificial Intelligence (AI) in Diagnostics Market in Italy (2022-2032)
  • Table 16: Artificial Intelligence (AI) in Diagnostics Market in Spain (2022-2032)
  • Table 17: Artificial Intelligence (AI) in Diagnostics Market in the Rest of Europe (2022-2032)
  • Table 18: Artificial Intelligence (AI) in Diagnostics Market in Asia-Pacific (2022-2032)
  • Table 19: Artificial Intelligence (AI) in Diagnostics Market in China (2022-2032)
  • Table 20: Artificial Intelligence (AI) in Diagnostics Market in Japan (2022-2032)
  • Table 21: Artificial Intelligence (AI) in Diagnostics Market in India (2022-2032)
  • Table 22: Artificial Intelligence (AI) in Diagnostics Market in Australia (2022-2032)
  • Table 23: Artificial Intelligence (AI) in Diagnostics Market in South Korea (2022-2032)
  • Table 24: Artificial Intelligence (AI) in Diagnostics Market in Rest of Asia-Pacific (2022-2032)
  • Table 25: Artificial Intelligence (AI) in Diagnostics Market in the Rest of the World (2022-2032)
  • Table 26: Artificial Intelligence (AI) in Diagnostics Market in the Middle East (2022-2032)
  • Table 27: Artificial Intelligence (AI) in Diagnostics Market in Africa (2022-2032)
  • Table 28: Artificial Intelligence (AI) in Diagnostics Market in South America (2022-2032)

List of Figures

  • Figure 1: Competitive Analysis
  • Figure 2: Artificial Intelligence (AI) in Diagnostics Market in Global (2022-2032)
  • Figure 3: Artificial Intelligence (AI) in Diagnostics Market in Global by Component (2022-2032)
  • Figure 4: Artificial Intelligence (AI) in Diagnostics Market in Global by Application (2022-2032)
  • Figure 5: Artificial Intelligence (AI) in Diagnostics Market in Global by Technology (2022-2032)
  • Figure 6: Artificial Intelligence (AI) in Diagnostics Market in Global by Geography (2022-2032)
  • Figure 7: Artificial Intelligence (AI) in Diagnostics Market in North America (2022-2032)
  • Figure 8: Artificial Intelligence (AI) in Diagnostics Market in the United States (2022-2032)
  • Figure 9: Artificial Intelligence (AI) in Diagnostics Market in Canada (2022-2032)
  • Figure 10: Artificial Intelligence (AI) in Diagnostics Market in Mexico (2022-2032)
  • Figure 11: Artificial Intelligence (AI) in Diagnostics Market in Europe (2022-2032)
  • Figure 12: Artificial Intelligence (AI) in Diagnostics Market in France (2022-2032)
  • Figure 13: Artificial Intelligence (AI) in Diagnostics Market in Germany (2022-2032)
  • Figure 14: Artificial Intelligence (AI) in Diagnostics Market in United Kingdom (2022-2032)
  • Figure 15: Artificial Intelligence (AI) in Diagnostics Market in Italy (2022-2032)
  • Figure 16: Artificial Intelligence (AI) in Diagnostics Market in Spain (2022-2032)
  • Figure 17: Artificial Intelligence (AI) in Diagnostics Market in the Rest of Europe (2022-2032)
  • Figure 18: Artificial Intelligence (AI) in Diagnostics Market in Asia-Pacific (2022-2032)
  • Figure 19: Artificial Intelligence (AI) in Diagnostics Market in China (2022-2032)
  • Figure 20: Artificial Intelligence (AI) in Diagnostics Market in Japan (2022-2032)
  • Figure 21: Artificial Intelligence (AI) in Diagnostics Market in India (2022-2032)
  • Figure 22: Artificial Intelligence (AI) in Diagnostics Market in Australia (2022-2032)
  • Figure 23: Artificial Intelligence (AI) in Diagnostics Market in South Korea (2022-2032)
  • Figure 24: Artificial Intelligence (AI) in Diagnostics Market in Rest of Asia-Pacific (2022-2032)
  • Figure 25: Artificial Intelligence (AI) in Diagnostics Market in the Rest of the World (2022-2032)
  • Figure 26: Artificial Intelligence (AI) in Diagnostics Market in the Middle East (2022-2032)
  • Figure 27: Artificial Intelligence (AI) in Diagnostics Market in Africa (2022-2032)
  • Figure 28: Artificial Intelligence (AI) in Diagnostics Market in South America (2022-2032)
  • Figure 28: Market Drivers
  • Figure 30: Market Barriers
  • Figure 31: Marker Opportunities
  • Figure 32: PORTER'S Five Force Analysis
目次
Product Code: DIMDCL0864

Artificial Intelligence (AI) in Diagnostics Market by Component (Hardware/software, and Services), Application (Infectious Disease Diagnostics, Radiology, Oncology, Cardiology, and Others), Technology (Machine Learning, Natural Language Processing, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World) is expected to grow at a steady CAGR forecast till 2032 owing to the rising cases of infectious and chronic diseases, growing adoption of digital health & imaging technologies, increase in product development activities among the key market players across the globe.

The Artificial Intelligence (AI) in Diagnostics market was valued at USD 1,623.20 million in 2024, growing at a CAGR of 22.31% during the forecast period from 2025 to 2032 to reach USD 8,081.97 million by 2032. The rising prevalence of infectious and chronic diseases is driving the demand for early and accurate diagnosis, where AI plays a vital role by enhancing detection and supporting faster clinical decisions. Simultaneously, the growing adoption of digital health and imaging technologies provides a strong foundation for integrating AI tools into existing healthcare workflows, improving efficiency and accuracy. Additionally, increased product development activities by key players across the globe fueled by advancements in machine learning and growing regulatory support are expanding the availability of AI-powered diagnostic solutions. Together, these factors are expected to significantly boost the global market for Artificial Intelligence (AI) in Diagnostics by enabling more precise, timely, and scalable healthcare delivery during the forecast period from 2025 to 2032.

Artificial Intelligence (AI) in Diagnostics Market Dynamics:

According to the data provided by the World Health Organization, in 2023, globally, an estimated 39.9 million people were living with HIV and approximately 1.3 million population acquired HIV. Additionally, as per the same source, in 2023, approximately 10.8 million people fell ill with tuberculosis (TB). Artificial Intelligence (AI) in Diagnostics is boosting the management of TB and HIV by enabling early detection and efficient monitoring. In TB, AI analyzes chest X-rays and CT scans to identify infection patterns, reducing reliance on radiologists, especially in low-resource areas. For HIV, AI supports disease progression tracking, treatment prediction, and detection of co-infections. These capabilities streamline workflows, reduce diagnostic delays, and enhance large-scale screening efforts.

Moreover, the rising global incidence of cancer is a major factor driving the growth of Artificial Intelligence (AI) in Diagnostics market. Cancer diagnosis often involves complex imaging, pathology, and genomic data, making it an ideal application for artificial intelligence. According, to the data provided by the World Health Organization (2024), in 2022, globally, there were an estimated 20 million new cancer cases with lung cancer being the most commonly occurring cancer worldwide with 2.5 million new cases accounting for 12.4% of the total new cases. AI-powered diagnostic tools, particularly those using CT scans and X-rays, are capable of detecting subtle signs of lung cancer that might be missed by the human eye. AI algorithms analyze imaging data to identify nodules, masses, and irregularities in lung tissues, allowing for quicker and more accurate detection.

In addition, according to data provided by the British Heart Foundation (2025), globally, around 640 million people were living with heart and circulatory diseases across the world. These diseases require precise and timely detection, as early diagnosis can greatly improve outcomes and reduce mortality rates. AI tools are increasingly being integrated into the diagnostic workflow to analyze medical imaging (e.g., CT, MRI, echocardiograms) and interpret complex data with higher accuracy and efficiency than traditional methods thereby escalating the overall market of Artificial Intelligence (AI) in Diagnostics.

Furthermore, the growing adoption of digital health and imaging technologies is boosting the AI diagnostics market by improving the speed, accuracy, and accessibility of medical diagnoses. AI algorithms efficiently analyze complex imaging data from CT scans, MRIs, and X-rays, aiding early detection in fields like oncology, cardiology, and pulmonology. For instance, in December 2024, GE HealthCare's Sonic DL AI MRI algorithm, launched at the RSNA 2024 conference, accelerates scans by up to 86% while enhancing image resolution for brain, spine, orthopedic, and body imaging.

Together, the above-mentioned factors are expected to boost the overall market of Artificial Intelligence (AI) in Diagnostics.

Despite these promising growth factors, the Artificial Intelligence (AI) in Diagnostics market faces challenges such as data privacy & security. Additionally, AI algorithms require large, high-quality datasets to train effectively, and integrating with existing healthcare systems can be challenging which may hinder the future market of Artificial Intelligence (AI) in Diagnostics during the forecast period.

Artificial Intelligence (AI) in Diagnostics Market Segment Analysis:

Artificial Intelligence (AI) in Diagnostics Market by Component (Hardware/software, and Services), Application (Infectious Disease Diagnostics, Radiology, Oncology, Cardiology, and Others), Technology (Machine Learning, Natural Language Processing, and Others), and Geography (North America, Europe, Asia-Pacific, and Rest of the World).

In the component segment of the Artificial Intelligence (AI) in Diagnostics market, the software category is projected to capture a significant revenue share in 2024. Software solutions are playing a pivotal role in boosting the overall market of Artificial Intelligence (AI) in Diagnostics by significantly enhancing the capabilities of diagnostic tools, improving accuracy, and streamlining clinical workflows.

These software systems integrate AI algorithms with various medical devices, such as imaging machines (CT scans, MRIs, X-rays), laboratory testing equipment, and patient monitoring systems, enabling real-time analysis and interpretation of complex data. AI-powered diagnostic software can process large volumes of data rapidly, identifying patterns and anomalies that human clinicians might miss. For instance, in imaging, AI software helps detect early signs of diseases such as cancer, cardiovascular conditions, and neurological disorders by analyzing medical images for subtle irregularities that may not be visible to the naked eye. In pathology, AI software assists in the classification and grading of tumors or detecting abnormalities in tissue samples, which aids in accurate diagnosis and treatment planning.

Moreover, software innovations are driving advancements in personalized medicine by analyzing patient data to predict disease progression, identify the most effective treatment plans, and monitor ongoing responses to treatment. This capability is particularly valuable in chronic disease management, such as in diabetes, heart disease, and oncology, where continuous monitoring is essential for adjusting treatments and preventing complications. The automation provided by AI software also helps reduce diagnostic errors, minimize human workload, and enhance the efficiency of healthcare professionals, allowing them to focus more on patient care rather than time-consuming manual tasks. Furthermore, the integration of AI diagnostic software with electronic health records (EHRs) enables seamless data sharing across different healthcare systems, improving collaboration among specialists and ensuring more coordinated care. The growing availability of cloud-based AI diagnostic software solutions further supports scalability, making advanced diagnostic tools more accessible to healthcare providers, especially in underserved or resource-limited regions. As more software solutions are developed and validated, the AI diagnostics market is experiencing rapid growth.

Additionally, the increase in product development activities such as product launches and product approvals are further escalating the overall market. For instance, in July 2024, Tempus received FDA 510(k) clearance for its ECG-AF algorithm, an AI-based tool designed to identify patients at increased risk of atrial fibrillation (AFib). ECG-AF is the first of a suite of next-generation diagnostics that Tempus has designed to identify patients at risk for a variety of cardiovascular conditions.

Given these factors, the software segment is expected to witness robust growth during the forecast period, thereby driving the overall expansion of Artificial Intelligence (AI) in Diagnostics market.

North America is expected to dominate the overall Artificial Intelligence (AI) in Diagnostics market:

North America is projected to account for the largest share of Artificial Intelligence (AI) in Diagnostics market in 2024. This dominance can be attributed to several key factors, including the rising prevalence of chronic and infectious diseases, increased adoption of imagining technologies, robust research and development (R&D) efforts, a well-established healthcare infrastructure, and a favorable regulatory environment that supports product launches and approvals.

According to the data provided by the International Agency for Research on Cancer, in 2022, the estimated number of new cases of brain cancer was 24,940 and the projections were estimated to increase 31,278 cases by 2045. AI technologies, particularly those used in medical imaging like MRI and CT scans, play a crucial role in identifying brain tumors, pinpointing their exact location, and assessing their size and characteristics with high precision. AI algorithms can analyze complex brain scans faster and with greater accuracy than traditional methods, detecting even subtle signs of tumors that might be missed by human radiologists thereby escalating the need for Artificial Intelligence (AI) in Diagnostics across the region.

According to the data provided by the Government of Canada, in 2022, there were, 13,953 cases of syphilis were reported in Canada, marking an 11% increase from 2021. AI-powered diagnostic systems, such as those integrating machine learning with laboratory testing and imaging, can improve the speed and accuracy of syphilis detection. AI algorithms can analyze large datasets of medical images (such as syphilis-related lesions in oral, genital, or anal regions) and blood tests (like serologic tests), identifying subtle patterns or abnormalities that may be difficult to detect manually.

Additionally, the region benefits from ongoing advancements in Artificial Intelligence (AI) in Diagnostics -related R&D, product launches, and regulatory approvals. Such developments further accelerate market expansion. For instance, in October 2024, Owkin introduced MSIntuit(R) CRC v2, a next-generation AI diagnostic tool to improve colorectal cancer (CRC) detection.

In summary, the combination of a high disease burden, innovative R&D landscape, advanced healthcare infrastructure, and favorable regulatory policies makes North America a leading market for AI in Diagnostic market throughout the forecast period.

Artificial Intelligence (AI) in Diagnostics Key Players:

Some of the key market players operating in the Artificial Intelligence (AI) in Diagnostics market include Aidoc, Owkin, Inc., Siemens Healthineers, PathAI, Ibex, Owkin, Inc., Imagen Technologies, Aiforia, RADLogics, Terarecon, Inc., Prenosis, Inc., Ibex, Google LLC, GE HealthCare, DreaMed, Riverain Technologies, Terarecon, Inc., Aiforia, RADLogics, and others.

Recent Developmental Activities in the Artificial Intelligence (AI) in Diagnostics Market:

  • In September 2024, Ibex Medical Analytics (Ibex), a leader in AI-powered cancer diagnostics, introduced the latest advancements in its innovative product platform, Ibex-AI. These new features, developed in collaboration with expert pathologists worldwide who actively use the platform in routine clinical practice, highlight Ibex's ongoing commitment to creating cutting-edge diagnostic tools tailored to the needs of healthcare professionals on the frontlines of patient care.
  • In October 2023, Lucida Medical Ltd, announced that it received Class IIb CE certification for its AI-powered prostate cancer detection software, Prostate IntelligenceTM (PiTM) Leveraging advanced AI technology, PiTM analyzes MRI scans and is seamlessly integrated into the radiologist's workflow.
  • In March 2023, Qritive launched its latest AI-driven innovation QAi Prostate, designed specifically for prostate cancer diagnosis. Utilizing cutting-edge machine learning algorithms, QAi Prostate analyzes whole slide images of prostate core needle biopsies with high precision.

Key Takeaways from the Artificial Intelligence (AI) in Diagnostics Market Report Study

  • Market size analysis for current Artificial Intelligence (AI) in Diagnostics market size (2024), and market forecast for 8 years (2025 to 2032)
  • Top key product/technology developments, mergers, acquisitions, partnerships, and joint ventures happened over the last 3 years.
  • Key companies dominating the Artificial Intelligence (AI) in Diagnostics market.
  • Various opportunities available for the other competitors in Artificial Intelligence (AI) in Diagnostics market space.
  • What are the top-performing segments in 2024? How these segments will perform in 2032?
  • Which are the top-performing regions and countries in the current Artificial Intelligence (AI) in Diagnostics market scenario?
  • Which are the regions and countries where companies should have concentrated on opportunities for Artificial Intelligence (AI) in Diagnostics market growth in the coming future?

Target Audience Who Can be benefited from this Artificial Intelligence (AI) in Diagnostics Market Report Study

  • Artificial Intelligence (AI) in Diagnostics product providers
  • Research organizations and consulting companies
  • Artificial Intelligence (AI) in Diagnostics-related organizations, associations, forums, and other alliances
  • Government and corporate offices
  • Start-up companies, venture capitalists, and private equity firms
  • Distributors and traders dealing in Artificial Intelligence (AI) in Diagnostics
  • Various end-users who want to know more about the Artificial Intelligence (AI) in Diagnostics market and the latest technological developments in the Artificial Intelligence (AI) in Diagnostics market.

Frequently Asked Questions for the Artificial Intelligence (AI) in Diagnostics Market:

1. What is Artificial Intelligence (AI) in Diagnostics?

  • Artificial Intelligence (AI) in Diagnostics refers to the use of artificial intelligence technologies, such as machine learning and deep learning algorithms, to analyze medical data (such as images, lab results, or patient records) to assist in diagnosing diseases and conditions. AI can enhance diagnostic accuracy, speed, and efficiency by detecting patterns or abnormalities that might be overlooked by human clinicians. It is widely used in areas like medical imaging, pathology, genomics, and disease monitoring, helping healthcare professionals make more informed decisions and improve patient outcomes.

2. What is the market for Artificial Intelligence (AI) in Diagnostics?

  • The Artificial Intelligence (AI) in Diagnostics market was valued at USD 1,623.20 million in 2024, growing at a CAGR of 22.31% during the forecast period from 2025 to 2032 to reach USD 8,081.97 million by 2032.

3. What are the drivers for the global Artificial Intelligence (AI) in Diagnostics market?

  • The rising prevalence of infectious and chronic diseases is driving the demand for early and accurate diagnosis, where AI plays a vital role by enhancing detection and supporting faster clinical decisions. Simultaneously, the growing adoption of digital health and imaging technologies provides a strong foundation for integrating AI tools into existing healthcare workflows, improving efficiency and accuracy. Additionally, increased product development activities by key players across the globe-fueled by advancements in machine learning and growing regulatory support-are expanding the availability of AI-powered diagnostic solutions. Together, these factors are expected to significantly boost the global market for Artificial Intelligence (AI) in Diagnostics by enabling more precise, timely, and scalable healthcare delivery during the forecast period from 2025 to 2032.

4. Who are the key players operating in the global Artificial Intelligence (AI) in Diagnostics market?

  • Some of the key market players operating in the Artificial Intelligence (AI) in Diagnostics market include Aidoc, Owkin, Inc., Siemens Healthineers, PathAI, Ibex, Owkin, Inc., Imagen Technologies, Aiforia, RADLogics, Terarecon, Inc., Prenosis, Inc., Ibex, Google LLC, GE HealthCare, DreaMed, Riverain Technologies, Terarecon, Inc., Aiforia, RADLogics, and others.

5. Which region has the highest share in the global Artificial Intelligence (AI) in Diagnostics market?

  • North America is projected to account for the largest share of the Artificial Intelligence (AI) in Diagnostics market in 2024. This dominance can be attributed to several key factors, including the rising prevalence of chronic and infectious diseases, increased adoption of imagining technologies, robust research and development (R&D) efforts, a well-established healthcare infrastructure, and a favorable regulatory environment that supports product launches and approvals.

Table of Contents

1. Artificial Intelligence (AI) in Diagnostics Market Report Introduction

  • 1.1. Scope of the Study
  • 1.2. Market Segmentation
  • 1.3. Market Assumption

2. Artificial Intelligence (AI) in Diagnostics Market Executive Summary

  • 2.1. Market at Glance

3. Competitive Landscape

4. Regulatory Analysis

5. Artificial Intelligence (AI) in Diagnostics Market Key Factors Analysis

  • 5.1. Artificial Intelligence (AI) in Diagnostics Market Drivers
    • 5.1.1. Rising cases of infectious and chronic diseases
    • 5.1.2. Growing adoption of digital health & imaging technologies
    • 5.1.3. Increase in product development activities among the key market players across the globe
  • 5.2. Artificial Intelligence (AI) in Diagnostics Market Restraints and Challenges
    • 5.2.1. Data privacy and security
    • 5.2.2. Low data quality and quantity
  • 5.3. Artificial Intelligence (AI) in Diagnostics Market Opportunities
    • 5.3.1. Ongoing research and development in integrating AI for rare and undiagnosed diseases

6. Artificial Intelligence (AI) in Diagnostics Market Porter's Five Forces Analysis

  • 6.1. Bargaining Power of Suppliers
  • 6.2. Bargaining Power of Consumers
  • 6.3. Threat of New Entrants
  • 6.4. Threat of Substitutes
  • 6.5. Competitive Rivalry

7. Artificial Intelligence (AI) in Diagnostics Market Assessment

  • 7.1. By Component
    • 7.1.1. Hardware/Software
    • 7.1.2. Services
  • 7.2. By Application
    • 7.2.1. Infectious Disease Diagnostics
    • 7.2.2. Radiology
    • 7.2.3. Oncology
    • 7.2.4. Cardiology
    • 7.2.5. Others
  • 7.3. By Technology
    • 7.3.1. Machine Learning
    • 7.3.2. Natural Language Processing
    • 7.3.3. Others
  • 7.4. By Geography
    • 7.4.1. North America
      • 7.4.1.1. United States Artificial Intelligence (AI) in Diagnostics Market Size in USD million (2022-2032)
      • 7.4.1.2. Canada Artificial Intelligence (AI) in Diagnostics Market Size in USD million (2022-2032)
      • 7.4.1.3. Mexico Artificial Intelligence (AI) in Diagnostics Market Size in USD million (2022-2032)
    • 7.4.2. Europe
      • 7.4.2.1. France Artificial Intelligence (AI) in Diagnostics Market Size in USD million (2022-2032)
      • 7.4.2.2. Germany Artificial Intelligence (AI) in Diagnostics Market Size in USD million (2022-2032)
      • 7.4.2.3. United Kingdom Artificial Intelligence (AI) in Diagnostics Market Size in USD million (2022-2032)
      • 7.4.2.4. Italy Artificial Intelligence (AI) in Diagnostics Market Size in USD million (2022-2032)
      • 7.4.2.5. Spain Artificial Intelligence (AI) in Diagnostics Market Size in USD million (2022-2032)
      • 7.4.2.6. Rest of Europe Artificial Intelligence (AI) in Diagnostics Market Size in USD million (2022-2032)
    • 7.4.3. Asia-Pacific
      • 7.4.3.1. China Artificial Intelligence (AI) in Diagnostics Market Size in USD million (2022-2032)
      • 7.4.3.2. Japan Artificial Intelligence (AI) in Diagnostics Market Size in USD million (2022-2032)
      • 7.4.3.3. India Artificial Intelligence (AI) in Diagnostics Market Size in USD million (2022-2032)
      • 7.4.3.4. Australia Artificial Intelligence (AI) in Diagnostics Market Size in USD million (2022-2032)
      • 7.4.3.5. South Korea Artificial Intelligence (AI) in Diagnostics Market Size in USD million (2022-2032)
      • 7.4.3.6. Rest of Asia-Pacific Artificial Intelligence (AI) in Diagnostics Market Size in USD million (2022-2032)
    • 7.4.4. Rest of the World (RoW)
      • 7.4.4.1. Middle East Artificial Intelligence (AI) in Diagnostics Market Size in USD million (2022-2032)
      • 7.4.4.2. Africa Artificial Intelligence (AI) in Diagnostics Market Size in USD million (2022-2032)
      • 7.4.4.3. South America Artificial Intelligence (AI) in Diagnostics Market Size in USD million (2022-2032)

8. Artificial Intelligence (AI) in Diagnostics Market Company and Product Profiles

  • 8.1. Aidoc
    • 8.1.1. Company Overview
    • 8.1.2. Company Snapshot
    • 8.1.3. Financial Overview
    • 8.1.4. Product Listing
    • 8.1.5. Entropy
  • 8.2. Qure.ai
    • 8.2.1. Company Overview
    • 8.2.2. Company Snapshot
    • 8.2.3. Financial Overview
    • 8.2.4. Product Listing
    • 8.2.5. Entropy
  • 8.3. GE HealthCare
    • 8.3.1. Company Overview
    • 8.3.2. Company Snapshot
    • 8.3.3. Financial Overview
    • 8.3.4. Product Listing
    • 8.3.5. Entropy
  • 8.4. Siemens Healthineers
    • 8.4.1. Company Overview
    • 8.4.2. Company Snapshot
    • 8.4.3. Financial Overview
    • 8.4.4. Product Listing
    • 8.4.5. Entropy
  • 8.5. PathAI
    • 8.5.1. Company Overview
    • 8.5.2. Company Snapshot
    • 8.5.3. Financial Overview
    • 8.5.4. Product Listing
    • 8.5.5. Entropy
  • 8.6. Ibex
    • 8.6.1. Company Overview
    • 8.6.2. Company Snapshot
    • 8.6.3. Financial Overview
    • 8.6.4. Product Listing
    • 8.6.5. Entropy
  • 8.7. Owkin, Inc
    • 8.7.1. Company Overview
    • 8.7.2. Company Snapshot
    • 8.7.3. Financial Overview
    • 8.7.4. Product Listing
    • 8.7.5. Entropy
  • 8.8. Imagen Technologies
    • 8.8.1. Company Overview
    • 8.8.2. Company Snapshot
    • 8.8.3. Financial Overview
    • 8.8.4. Product Listing
    • 8.8.5. Entropy
  • 8.9. Aiforia
    • 8.9.1. Company Overview
    • 8.9.2. Company Snapshot
    • 8.9.3. Financial Overview
    • 8.9.4. Product Listing
    • 8.9.5. Entropy
  • 8.10. RADLogics
    • 8.10.1. Company Overview
    • 8.10.2. Company Snapshot
    • 8.10.3. Financial Overview
    • 8.10.4. Product Listing
    • 8.10.5. Entropy
  • 8.11. Terarecon, Inc.
    • 8.11.1. Company Overview
    • 8.11.2. Company Snapshot
    • 8.11.3. Financial Overview
    • 8.11.4. Product Listing
    • 8.11.5. Entropy
  • 8.12. Prenosis, Inc.
    • 8.12.1. Company Overview
    • 8.12.2. Company Snapshot
    • 8.12.3. Financial Overview
    • 8.12.4. Product Listing
    • 8.12.5. Entropy
  • 8.13. Ibex
    • 8.13.1. Company Overview
    • 8.13.2. Company Snapshot
    • 8.13.3. Financial Overview
    • 8.13.4. Product Listing
    • 8.13.5. Entropy
  • 8.14. Google LLC
    • 8.14.1. Company Overview
    • 8.14.2. Company Snapshot
    • 8.14.3. Financial Overview
    • 8.14.4. Product Listing
    • 8.14.5. Entropy
  • 8.15. GE HealthCare
    • 8.15.1. Company Overview
    • 8.15.2. Company Snapshot
    • 8.15.3. Financial Overview
    • 8.15.4. Product Listing
    • 8.15.5. Entropy
  • 8.16. DreaMed
    • 8.16.1. Company Overview
    • 8.16.2. Company Snapshot
    • 8.16.3. Financial Overview
    • 8.16.4. Product Listing
    • 8.16.5. Entropy
  • 8.17. Riverain Technologies
    • 8.17.1. Company Overview
    • 8.17.2. Company Snapshot
    • 8.17.3. Financial Overview
    • 8.17.4. Product Listing
    • 8.17.5. Entropy
  • 8.18. Terarecon, Inc.
    • 8.18.1. Company Overview
    • 8.18.2. Company Snapshot
    • 8.18.3. Financial Overview
    • 8.18.4. Product Listing
    • 8.18.5. Entropy
  • 8.19. Aiforia
    • 8.19.1. Company Overview
    • 8.19.2. Company Snapshot
    • 8.19.3. Financial Overview
    • 8.19.4. Product Listing
    • 8.19.5. Entropy
  • 8.20. RADLogics
    • 8.20.1. Company Overview
    • 8.20.2. Company Snapshot
    • 8.20.3. Financial Overview
    • 8.20.4. Product Listing
    • 8.20.5. Entropy

9. KOL Views

10. Project Approach

11. About DelveInsight

12. Disclaimer & Contact Us